vs

Side-by-side financial comparison of SurgePays, Inc. (SURG) and UTAH MEDICAL PRODUCTS INC (UTMD). Click either name above to swap in a different company.

SurgePays, Inc. is the larger business by last-quarter revenue ($16.2M vs $9.0M, roughly 1.8× UTAH MEDICAL PRODUCTS INC). UTAH MEDICAL PRODUCTS INC runs the higher net margin — 28.4% vs -85.6%, a 114.0% gap on every dollar of revenue. On growth, SurgePays, Inc. posted the faster year-over-year revenue change (68.7% vs -1.2%). Over the past eight quarters, UTAH MEDICAL PRODUCTS INC's revenue compounded faster (-10.7% CAGR vs -28.2%).

SurgePays, Inc. is a U.S.-headquartered fintech and telecommunications company focused on serving underbanked and low-income communities across the country. It offers prepaid wireless plans, reloadable debit cards, digital banking solutions, and daily consumer products through a nationwide network of independent local retail partners such as convenience stores.

Varian Medical Systems is an American radiation oncology treatments and software maker based in Palo Alto, California. Their medical devices include linear accelerators (LINACs) and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies software for managing cancer clinics, radiotherapy centers, and medical oncology practices. Varian Medical Systems employs more than 7,100 people at manufacturing sites...

SURG vs UTMD — Head-to-Head

Bigger by revenue
SURG
SURG
1.8× larger
SURG
$16.2M
$9.0M
UTMD
Growing faster (revenue YoY)
SURG
SURG
+69.9% gap
SURG
68.7%
-1.2%
UTMD
Higher net margin
UTMD
UTMD
114.0% more per $
UTMD
28.4%
-85.6%
SURG
Faster 2-yr revenue CAGR
UTMD
UTMD
Annualised
UTMD
-10.7%
-28.2%
SURG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SURG
SURG
UTMD
UTMD
Revenue
$16.2M
$9.0M
Net Profit
$-13.9M
$2.6M
Gross Margin
-14.8%
58.2%
Operating Margin
-79.1%
27.0%
Net Margin
-85.6%
28.4%
Revenue YoY
68.7%
-1.2%
Net Profit YoY
30.0%
-11.6%
EPS (diluted)
$-0.68
$0.80

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SURG
SURG
UTMD
UTMD
Q4 25
$16.2M
$9.0M
Q3 25
$18.7M
$9.8M
Q2 25
$11.5M
$10.0M
Q1 25
$10.6M
$9.7M
Q4 24
$9.6M
$9.2M
Q3 24
$4.8M
$10.0M
Q2 24
$15.1M
$10.4M
Q1 24
$31.4M
$11.3M
Net Profit
SURG
SURG
UTMD
UTMD
Q4 25
$-13.9M
$2.6M
Q3 25
$-7.5M
$2.6M
Q2 25
$-7.1M
$3.0M
Q1 25
$-7.6M
$3.0M
Q4 24
$-19.8M
$2.9M
Q3 24
$-14.3M
$3.6M
Q2 24
$-12.9M
$3.5M
Q1 24
$1.2M
$4.0M
Gross Margin
SURG
SURG
UTMD
UTMD
Q4 25
-14.8%
58.2%
Q3 25
-13.9%
57.1%
Q2 25
-23.0%
56.2%
Q1 25
-27.8%
57.0%
Q4 24
-117.0%
58.1%
Q3 24
-164.2%
58.0%
Q2 24
-22.8%
60.1%
Q1 24
26.0%
59.7%
Operating Margin
SURG
SURG
UTMD
UTMD
Q4 25
-79.1%
27.0%
Q3 25
-37.2%
26.6%
Q2 25
-59.1%
32.1%
Q1 25
-71.7%
32.5%
Q4 24
-209.0%
32.0%
Q3 24
-299.4%
33.4%
Q2 24
-72.1%
33.1%
Q1 24
5.6%
34.2%
Net Margin
SURG
SURG
UTMD
UTMD
Q4 25
-85.6%
28.4%
Q3 25
-40.1%
26.8%
Q2 25
-61.5%
30.6%
Q1 25
-72.2%
31.3%
Q4 24
-206.5%
31.7%
Q3 24
-299.3%
35.6%
Q2 24
-85.3%
33.2%
Q1 24
3.9%
34.9%
EPS (diluted)
SURG
SURG
UTMD
UTMD
Q4 25
$-0.68
$0.80
Q3 25
$-0.38
$0.82
Q2 25
$-0.36
$0.94
Q1 25
$-0.38
$0.92
Q4 24
$-1.07
$0.86
Q3 24
$-0.73
$1.03
Q2 24
$-0.66
$0.98
Q1 24
$0.07
$1.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SURG
SURG
UTMD
UTMD
Cash + ST InvestmentsLiquidity on hand
$1.7M
$85.8M
Total DebtLower is stronger
$13.3M
$225.0K
Stockholders' EquityBook value
$-15.3M
$119.3M
Total Assets
$8.5M
$122.5M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SURG
SURG
UTMD
UTMD
Q4 25
$1.7M
$85.8M
Q3 25
$2.5M
$84.3M
Q2 25
$4.4M
$82.2M
Q1 25
$5.4M
$83.3M
Q4 24
$11.8M
$83.0M
Q3 24
$23.7M
$88.5M
Q2 24
$89.2M
Q1 24
$93.8M
Total Debt
SURG
SURG
UTMD
UTMD
Q4 25
$13.3M
$225.0K
Q3 25
$12.0M
Q2 25
$9.6M
Q1 25
$3.6M
$269.0K
Q4 24
$4.0M
$282.0K
Q3 24
$4.4M
Q2 24
$4.8M
Q1 24
$5.2M
Stockholders' Equity
SURG
SURG
UTMD
UTMD
Q4 25
$-15.3M
$119.3M
Q3 25
$-6.4M
$118.3M
Q2 25
$116.1K
$117.5M
Q1 25
$7.8M
$117.0M
Q4 24
$15.3M
$117.4M
Q3 24
$33.2M
$124.2M
Q2 24
$46.2M
$124.1M
Q1 24
$56.0M
$127.7M
Total Assets
SURG
SURG
UTMD
UTMD
Q4 25
$8.5M
$122.5M
Q3 25
$14.5M
$122.0M
Q2 25
$15.2M
$120.8M
Q1 25
$15.7M
$122.5M
Q4 24
$24.0M
$122.5M
Q3 24
$41.5M
$129.7M
Q2 24
$56.4M
$130.0M
Q1 24
$69.6M
$135.4M
Debt / Equity
SURG
SURG
UTMD
UTMD
Q4 25
0.00×
Q3 25
Q2 25
82.67×
Q1 25
0.46×
0.00×
Q4 24
0.26×
0.00×
Q3 24
0.13×
Q2 24
0.10×
Q1 24
0.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SURG
SURG
UTMD
UTMD
Operating Cash FlowLast quarter
$-3.6M
$3.5M
Free Cash FlowOCF − Capex
$3.4M
FCF MarginFCF / Revenue
37.2%
Capex IntensityCapex / Revenue
1.2%
Cash ConversionOCF / Net Profit
1.36×
TTM Free Cash FlowTrailing 4 quarters
$14.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SURG
SURG
UTMD
UTMD
Q4 25
$-3.6M
$3.5M
Q3 25
$-4.6M
$3.9M
Q2 25
$-6.1M
$2.9M
Q1 25
$-7.0M
$4.5M
Q4 24
$-7.9M
$2.9M
Q3 24
$-13.3M
$3.9M
Q2 24
$-4.1M
$2.8M
Q1 24
$4.0M
$5.3M
Free Cash Flow
SURG
SURG
UTMD
UTMD
Q4 25
$3.4M
Q3 25
$3.9M
Q2 25
$2.8M
Q1 25
$4.3M
Q4 24
$2.9M
Q3 24
$3.8M
Q2 24
$2.7M
Q1 24
$5.3M
FCF Margin
SURG
SURG
UTMD
UTMD
Q4 25
37.2%
Q3 25
39.2%
Q2 25
28.4%
Q1 25
44.1%
Q4 24
32.0%
Q3 24
37.7%
Q2 24
25.5%
Q1 24
46.3%
Capex Intensity
SURG
SURG
UTMD
UTMD
Q4 25
1.2%
Q3 25
0.3%
Q2 25
0.5%
Q1 25
1.9%
Q4 24
0.1%
Q3 24
0.9%
Q2 24
1.1%
Q1 24
0.2%
Cash Conversion
SURG
SURG
UTMD
UTMD
Q4 25
1.36×
Q3 25
1.47×
Q2 25
0.94×
Q1 25
1.47×
Q4 24
1.01×
Q3 24
1.08×
Q2 24
0.80×
Q1 24
3.30×
1.33×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons